Hot High Tech Stocks To Watch Right Now

NEW YORK (TheStreet) -- Gold prices were plummeting on Thursday after a strong labor report compounded with a large selling order of gold that triggered a negative reaction among traders.

Gold for December delivery at the COMEX division of the New York Mercantile Exchange was falling $32.20 to $1,331.60 an ounce. The gold price traded as high as $1,366.20 and as low as $1,325.60 an ounce, while the spot price was diving $34.73.

The Labor Department reported Thursday that jobless claims for the week ending Sept. 7 dropped to 292,000, which was a decrease from the prior week's figure of 323,000. Economists surveyed by Thomson Reuters were expecting claims to rise to 330,000. Investors should note, however, that two states did not file jobless claims in the latest data, which could mean claims actually were higher than reported.

Hot High Tech Stocks To Watch Right Now: Tearlach Resources Limited (TEA.V)

Tearlach Resources Limited engages in the acquisition, exploration, and development of mineral, and oil and gas properties in Canada and the United States. The company primarily explores for nickel, copper, platinum, palladium, and other precious metal ores. Its properties include the Foy Hess Property located on the north range of the Sudbury Basin region of Ontario, Canada; and Kern Front Field, an oil and gas property situated in the north of Bakersfield, California. Tearlach Resources Limited is headquartered in Vancouver, Canada.

Hot High Tech Stocks To Watch Right Now: Birner Dental Management Services Inc.(BDMS)

Birner Dental Management Services, Inc., a dental business service company, provides dental practice management services to dental practice networks in Colorado, New Mexico, and Arizona. The company offers business services to 64 dental practice offices that include 38 acquired offices and 26 internally developed ?de novo Offices?. Its affiliated dentist offices provide general dentistry services, including crowns and bridges, fillings, and aesthetic procedures, such as porcelain veneers and bleaching; cleanings and periodontal services, including root planning and scaling; and specialty dental services, such as orthodontics, oral surgery, pediatrics, endodontics, and periodontics at some of its offices. The company serves dentists, patients, and third-party payors. Birner Dental Management Services, Inc. was founded in 1995 and is headquartered in Denver, Colorado.

Advisors' Opinion:

• [By Geoff Gannon]

  For example, a company involved in a mundane business like running hair salons ��like Regis (RGS), dentist offices ��like Birner Dental (BDMS), grocery stores ��like Village Supermarket (VLGEA), or garbage dumps ��like Waste Management (WM), may be easy to estimate as essentially a no-growth business.

• [By Geoff Gannon]

  I could go down the list for each company that I thought was an especially oddly valued stock. For Birner Dental (BDMS), it�� possible people were paying more attention to earnings per share and dividends than EBITDA and share buybacks. For Bancinsurance, the company�� top management was under SEC investigation. For George Risk (RSKIA), it was a combination of not really cheap on a P/E basis and just barely cheap on a cash basis ��and it was connected to homebuilding.

10 Best Energy Stocks To Watch Right Now: Vista Gold Corp Com Npv(VGZ.TO)

Vista Gold Corp. engages in the evaluation, acquisition, exploration, and advancement of gold exploration and potential development projects primarily in Australia, North America, and Indonesia. The company?s holdings comprise the Mt. Todd gold project in Australia; the Guadalupe de los Reyes gold/silver project in Mexico; the Concordia gold project in Mexico; the Awak Mas gold project in Indonesia; the Long Valley gold project in California; and mining claims in Utah. Vista Gold Corp. was founded in 1983 and is based in Littleton, Colorado.

Hot High Tech Stocks To Watch Right Now: Achillion Pharmaceuticals Inc.(ACHN)

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. The company focuses on the development of antivirals for the treatment of chronic hepatitis C; and the development of antibacterials for the treatment of resistant bacterial infections. Its drug candidates for the treatment of chronic HCV include ACH-1625, a protease inhibitor, which is in phase IIa clinical trial for the treatment of chronic HCV; ACH-2684, a pangenotypic protease inhibitor, which is in phase I clinical trial for the treatment of chronic HCV infection; and NS5A inhibitors for the treatment of chronic HCV infection, including ACH-2928, which is to enter a phase I clinical trial, as well as various additional NS5A inhibitors in preclinical development. Its pipeline of product candidates also includes ACH-702 and ACH-2881 for drug resistant bacterial infections; elvucitabine for HIV infection; and AC H-1095 for HCV infection. The company was founded in 1998 and is based in New Haven, Connecticut.

Advisors' Opinion:

• [By Roberto Pedone]

  An under-$10 biotechnology player that's starting to trend within range of triggering a big breakout trade is Achillion Pharmaceuticals (ACHN), discovers, develops and commercializes anti-infective drug therapies in the U.S. and internationally. This stock has been destroyed by the sellers so far in 2013, with shares down big by 66%.

  If you take a look at the chart for Achillion Pharmaceuticals, you'll notice that this stock has been trending sideways for the last month and change, with shares moving between $2.26 on the downside and $2.98 on the upside. This sideways trading pattern is occurring after shares of ACHN gapped down sharply in late September from $7.50 to under $3 with heavy downside volume. Shares of ACHN are now starting to trend higher and move within range of triggering a big breakout trade above the upper-end of its sideways trading chart pattern.

  Traders should now look for long-biased trades in ACHN if it manages to break out above some near-term overhead resistance levels at $2.85 to $2.98 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 2.76 million shares. If that breakout triggers soon, then ACHN will set up to re-test or possibly take out its gap down day high from September at $3.62 a share. Any high-volume move above that level will then give ACHN a chance to re-fill some of its previous gap down zone that started at $7.50 a share.

  Traders can look to buy ACHN off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $2.44 to $2.26 a share. One can also buy ACHN off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Grace L. Williams]

  We took a look at Achillion Pharmaceuticals (ACHN) after two directors bought 40,000 shares for $394,800. Dennis Liotta bought 20,000 shares for $158,100 and Jason Fisherman bought 20,000 shares for $155,000. InsiderScore gave Liotta a nod, writing, ��iotta has been a smart buyer at Achillion in the past. He bought the same number of shares here, this time at a price 28% higher, which is the highest price he has paid for shares.��/p>

Hot High Tech Stocks To Watch Right Now: Ebix Inc(EBIX)

Ebix, Inc. provides on-demand software and e-commerce solutions to the insurance industry. The company operates data exchanges, which connects multiple entities within the insurance markets and enables the participant to carry and process data from one end to another in the areas of life insurance, annuities, employee health benefits, risk management, workers compensation, and property and casualty (P&C) insurance. It is also involved in designing and deploying broker systems comprising three back-end systems consisting of eGlobal for multinational P&C insurance brokers; WinBeat for P&C brokers in the Australian and New Zealand markets; and EbixASP for the P&C insurance brokers in the United States. In addition, the company offers business process outsourcing services, which include certificate origination, certificate tracking, claims adjudication call center, and back office support. Further, it focuses on designing and deploying on-demand and back-end carrier systems, s uch as Ebix Advantage and Ebix Advantageweb targeted at small, medium, and large P&C carriers in the United States and internationally that operate in the personal, commercial, and specialty line areas of insurance. Additionally, Ebix, Inc. provides software development, customization, and consulting services to various companies in the insurance industry, such as carriers, brokers, exchanges, and standard making bodies. The company was formerly known as Delphi Systems, Inc. and changed its name to Ebix, Inc. in December 2003. Ebix, Inc. was founded in 1976 and is headquartered in Atlanta, Georgia.

Advisors' Opinion:

• [By Caroline Bennett]

  Ebix's� (NASDAQ: EBIX  ) latest earnings call�revealed�a 6.9% decrease in the company's quarterly revenue, dropping from $53.8 million in Q3 2012, to $50.3 million.�

• [By Roberto Pedone]

  One software player that's rapidly moving within range of triggering a big breakout trade is Ebix (EBIX), which provides a series of application software products for the insurance industry ranging from carrier systems, agency systems and exchanges to custom software development for all entities involved in the insurance and financial industries. This stock has been slammed hard by the bears so far in 2013, with shares off by 28%.

  If you look at the chart for Ebix, you'll notice that this stock has been uptrending for the last month, with shares moving higher from its low of $9.25 to its intraday high of $11.65 a share. During that uptrend, shares of EBIX have been consistently making higher lows and higher highs, which is bullish technical price action. That move is quickly pushing shares of EBIX within range of trigger a major breakout trade that could push the stock into a massive gap down zone from last June.

  Traders should now look for long-biased trades in EBIX if it manages to break out above some near-term overhead resistance levels at $11.74 to $12 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1.06 million shares. If that breakout triggers soon, then EBIX will set up to re-fill some of its previous gap down zone from June that started near $20 a share. Some possible upside targets if EBIX gets into that gap with volume are $14 to $16 a share.

  Traders can look to buy EBIX off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $10.87 a share or around more near-term support at $10.39 a share. One can also buy EBIX off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Taylor Muckerman]

  Better watch your book
  Ebix� (NASDAQ: EBIX  ) , an insurance software company, has been under investigation since last November but had denied these allegations initially. Just 13 days ago, an acquisition deal was called off by an arm of Goldman Sachs after further investigations were announced by the U.S. Attorney for the Northern District of Georgia. The stock reacted to the announcement by dropping 44% and 13% in the two days following as investors sold off. This reaction is justified in the fact that the probe surrounds alleged accounting misconduct.

• [By Dan Caplinger]

  The next question for the market depends on whether adverse market conditions lead to changes in strategic thinking. We've already seen one victim of that change: Insurance software and services provider Ebix (NASDAQ: EBIX  ) plunged more than 40% after investment firm Goldman Sachs (NYSE: GS) canceled a planned merger with a Goldman affiliate. M&A activity has increased recently, but falling markets often lead to fewer mergers actually going through and can also lead to reductions in IPOs coming to market as well. That's bad news for Goldman as well, which relies on underwriting such deals.